MCID: CRB008
MIFTS: 44

Cerebral Atherosclerosis

Categories: Cardiovascular diseases

Aliases & Classifications for Cerebral Atherosclerosis

MalaCards integrated aliases for Cerebral Atherosclerosis:

Name: Cerebral Atherosclerosis 12 56 15 17 74
Intracranial Arteriosclerosis 45 74

Classifications:



External Ids:

Disease Ontology 12 DOID:12720
ICD9CM 36 437.0
MeSH 45 D002537
NCIt 51 C34459
SNOMED-CT 69 55382008
ICD10 34 I67.2

Summaries for Cerebral Atherosclerosis

MalaCards based summary : Cerebral Atherosclerosis, also known as intracranial arteriosclerosis, is related to atherosclerosis susceptibility and stroke, ischemic. An important gene associated with Cerebral Atherosclerosis is MTHFR (Methylenetetrahydrofolate Reductase), and among its related pathways/superpathways are Metabolism of water-soluble vitamins and cofactors and Binding and Uptake of Ligands by Scavenger Receptors. The drugs Atorvastatin and Citalopram have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and smooth muscle, and related phenotypes are Decreased free cholesterol and Increased LDL uptake

Wikipedia : 77 Cerebral atherosclerosis is a type of atherosclerosis where build-up of plaque in the blood vessels of... more...

Related Diseases for Cerebral Atherosclerosis

Diseases related to Cerebral Atherosclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Related Disease Score Top Affiliating Genes
1 atherosclerosis susceptibility 30.0 APOA1 APOE
2 stroke, ischemic 29.9 ACE APOE MTHFR
3 sleep apnea 29.6 ACE APOE
4 hypercholesterolemia, familial 29.2 ACE APOA1 APOE
5 heart disease 29.1 ACE APOA1 APOE MTHFR
6 ischemic heart disease 28.9 ACE APOA1 APOE MTHFR
7 coronary heart disease 1 28.9 ACE APOA1 APOE MTHFR
8 cerebrovascular disease 28.9 ACE APOA1 APOE MTHFR
9 vascular disease 28.9 ACE APOA1 APOE MTHFR
10 intracranial arteriosclerosis 12.4
11 moderate and severe traumatic brain injury 10.1 ACE APOE
12 retinal artery occlusion 10.1 ACE MTHFR
13 generalized atherosclerosis 10.1 ACE APOE
14 exfoliation syndrome 10.1 APOE MTHFR
15 arteritic anterior ischemic optic neuropathy 10.1 ACE MTHFR
16 ischemic optic neuropathy 10.1 ACE MTHFR
17 aortic atherosclerosis 10.1 ACE APOE
18 nephrosclerosis 10.1 ACE MTHFR
19 migraine with aura 10.1 ACE MTHFR
20 nonarteritic anterior ischemic optic neuropathy 10.1 ACE MTHFR
21 hemorrhage, intracerebral 10.1 ACE APOE
22 retinal vascular disease 10.1 ACE MTHFR
23 familial lcat deficiency 10.1 APOA1 APOE
24 fibromuscular dysplasia 10.1 ACE RNF213
25 hepatic lipase deficiency 10.1 APOA1 APOE
26 hyperlipoproteinemia, type v 10.1 APOA1 APOE
27 leukodystrophy, hypomyelinating, 3 10.1 APOA1 APOE
28 hypolipoproteinemia 10.1 APOA1 APOE
29 hypertriglyceridemia, familial 10.0 APOA1 APOE
30 cerebral palsy 10.0 APOE MTHFR
31 hyperlipoproteinemia, type iii 10.0 APOA1 APOE
32 arcus corneae 10.0 APOA1 APOE
33 hyperalphalipoproteinemia 1 10.0 APOA1 APOE
34 lecithin:cholesterol acyltransferase deficiency 10.0 APOA1 APOE
35 inherited metabolic disorder 10.0 APOA1 MTHFR
36 gallbladder disease 10.0 APOA1 APOE
37 abetalipoproteinemia 10.0 APOA1 APOE
38 tangier disease 10.0 APOA1 APOE
39 alzheimer disease 10.0
40 familial hyperlipidemia 9.9 APOA1 APOE
41 peripheral vascular disease 9.9 ACE APOA1
42 carotid stenosis 9.9 ACE APOE MTHFR
43 vascular dementia 9.9 ACE APOE MTHFR
44 cerebral arterial disease 9.9 RNF213 RPSA
45 moyamoya disease 1 9.9 RNF213 RPSA
46 acquired metabolic disease 9.9 ACE APOA1
47 coronary stenosis 9.8 ACE APOA1 APOE
48 carotid artery disease 9.8 ACE APOA1 APOE
49 arteries, anomalies of 9.8 ACE APOA1 APOE
50 lipid metabolism disorder 9.8 ACE APOA1 APOE

Comorbidity relations with Cerebral Atherosclerosis via Phenotypic Disease Network (PDN): (show all 42)


Active Peptic Ulcer Disease Acute Cystitis
Alzheimer Disease Aortic Valve Disease 1
Basilar Artery Insufficiency Benign Essential Hypertension
Borderline Personality Disorder Bronchitis
Bronchopneumonia Cerebral Degeneration
Cerebrovascular Disease Chronic Kidney Failure
Chronic Myocardial Ischemia Decubitus Ulcer
Deficiency Anemia Encephalopathy
Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation Familial Atrial Fibrillation
Generalized Atherosclerosis Heart Disease
Hypertension, Essential Hypertensive Encephalopathy
Hypoglycemia Hypothyroidism
Intracranial Embolism Intracranial Thrombosis
Iron Deficiency Anemia Ischemic Heart Disease
Major Depressive Disorder Malignant Essential Hypertension
Osteoporosis Parkinson Disease, Late-Onset
Peripheral Vascular Disease Protein-Energy Malnutrition
Pseudobulbar Palsy Schizophreniform Disorder
Sinoatrial Node Disease Status Epilepticus
Swallowing Disorders Transient Cerebral Ischemia
Vascular Dementia Vertebral Artery Insufficiency

Graphical network of the top 20 diseases related to Cerebral Atherosclerosis:



Diseases related to Cerebral Atherosclerosis

Symptoms & Phenotypes for Cerebral Atherosclerosis

GenomeRNAi Phenotypes related to Cerebral Atherosclerosis according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 8.96 APOA1 APOE
2 Increased LDL uptake GR00340-A-1 8.62 APOA1 APOE

MGI Mouse Phenotypes related to Cerebral Atherosclerosis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.55 ACE APOA1 APOE RNF213 RPSA
2 endocrine/exocrine gland MP:0005379 9.35 ACE APOA1 APOE RNF213 RPSA
3 liver/biliary system MP:0005370 8.92 ACE APOA1 APOE MTHFR

Drugs & Therapeutics for Cerebral Atherosclerosis

Drugs for Cerebral Atherosclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 203)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Atorvastatin Approved Phase 4,Early Phase 1 134523-00-5 60823
2
Citalopram Approved Phase 4,Phase 3 59729-33-8 2771
3
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
4
Cilostazol Approved, Investigational Phase 4,Phase 3 73963-72-1 2754
5
Probucol Approved, Investigational Phase 4 23288-49-5 4912
6
Telmisartan Approved, Investigational Phase 4,Phase 3,Not Applicable 144701-48-4 65999
7
Amlodipine Approved Phase 4,Phase 3,Not Applicable 88150-42-9 2162
8
Angiotensin II Approved, Investigational Phase 4,Phase 3,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198
9
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
10
Atenolol Approved Phase 4 29122-68-7 2249
11
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
12
Propranolol Approved, Investigational Phase 4 525-66-6 4946
13
Hydrocodone Approved, Illicit, Investigational Phase 4 125-29-1 5284569
14
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
15
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
16
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
17
Donepezil Approved Phase 4,Phase 3,Phase 1 120014-06-4 3152
18
tannic acid Approved Phase 4 1401-55-4
19
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
20
Calcium Approved, Nutraceutical Phase 4,Phase 3,Not Applicable 7440-70-2 271
21
Corticosterone Experimental Phase 4 50-22-6 5753
22 Antimetabolites Phase 4,Phase 3,Phase 2,Early Phase 1
23 Rosuvastatin Calcium Phase 4 147098-20-2
24 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 2,Early Phase 1
25 Anticholesteremic Agents Phase 4,Phase 2,Early Phase 1
26 Lipid Regulating Agents Phase 4,Phase 3,Phase 2,Early Phase 1
27 Hypolipidemic Agents Phase 4,Phase 3,Phase 2,Early Phase 1
28 Calcium, Dietary Phase 4,Phase 3,Not Applicable
29 Antidepressive Agents Phase 4,Phase 3
30 Autonomic Agents Phase 4,Phase 2,Phase 3
31 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 3
32 Parasympatholytics Phase 4
33 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3
34 Serotonin Uptake Inhibitors Phase 4,Phase 3
35 Psychotropic Drugs Phase 4,Phase 3,Phase 2
36 Serotonin Agents Phase 4,Phase 3
37 Muscarinic Antagonists Phase 4
38 Antidepressive Agents, Second-Generation Phase 4,Phase 3
39 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
40 Cholinergic Antagonists Phase 4
41 Antiparkinson Agents Phase 4
42 Cholinergic Agents Phase 4,Phase 2,Phase 3,Phase 1
43 Phosphodiesterase Inhibitors Phase 4,Phase 3,Phase 2
44 Nootropic Agents Phase 4,Phase 2,Phase 3,Phase 1
45 Cholinesterase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
46 Phosphodiesterase 3 Inhibitors Phase 4,Phase 3
47 Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable
48 Fibrinolytic Agents Phase 4,Phase 3
49 Platelet Aggregation Inhibitors Phase 4,Phase 3,Not Applicable
50 Bronchodilator Agents Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 121)
# Name Status NCT ID Phase Drugs
1 Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis Unknown status NCT02458755 Phase 4 High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
2 Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia, and Mixed Vascular and Alzheimer’s Dementia Unknown status NCT00229333 Phase 4 Escitalopram
3 Clinical Trial of Efficacy and Safety of Divaza in the Management of Oxidative Disturbances in Cerebral Atherosclerosis Completed NCT03485495 Phase 4 Divaza;Placebo
4 Study of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject Completed NCT00823875 Phase 4 Cilostazol group;Probucol group;Cilostazol + Probucol group;control group
5 Trial Comparing Metabolic Effects of Telmisartan and Amlodipine on Hypertensive Patients With Obesity and Diabetes Completed NCT00847262 Phase 4 Temisartan;Amlodipine
6 Reducing Total Cardiovascular Risk in an Urban Community Completed NCT00241904 Phase 4 Antiplatelet Agents;Beta Blocker;ACE Inhibitors
7 A Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia Completed NCT00947531 Phase 4 Cerebrolysin;0.9% Saline Solution
8 Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions Completed NCT00847860 Phase 4 Cilostazol;Aspirin
9 Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT) Completed NCT00385684 Phase 4 hydrocodone/APAP w placebo PRN;hydrocodone/APAP;placebo with hydrocodone/APAP PRN
10 Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia Completed NCT00165763 Phase 4 donepezil hydrochloride (Aricept)
11 The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques Recruiting NCT03753555 Phase 4 Atorvastatin Calcium;Atorvastatin Calcium;Probucol
12 Imaging of Brain Amyloid Plaques in the Aging Population Enrolling by invitation NCT00950430 Phase 4 Pittsburgh Compound B (C-11 PiB);F-18 FDG;Tau (18-F-AV-1451)
13 Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial Atherosclerosis Terminated NCT01104311 Phase 4
14 Symptomatic Treatment of Vascular Cognitive Impairment Unknown status NCT02098824 Phase 2, Phase 3 Galantamine;Methylphenidate;Placebo
15 Evaluating the Effects of Music Interventions on Hospitalised People With Dementia Unknown status NCT00448318 Phase 2, Phase 3
16 Cilostazol-Aspirin Therapy Against Recurrent Stroke With Intracranial Artery Stenosis Completed NCT00333164 Phase 3 Asprin, Cilostazol
17 Cholesterol-Lowering Atherosclerosis Study (CLAS) Completed NCT00000599 Phase 3 colestipol;niacin
18 Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia Completed NCT02453932 Phase 3 Tianzhi granule and placebo identified to donepezil;Donepezil and placebo identified to Tianzhi granule;Placebo
19 Seroquel- Agitation Associated With Dementia Completed NCT00621647 Phase 3 Quetiapine Fumarate;Quetiapine Fumarate;Placebo
20 A Study of the Safety and Effectiveness of Galantamine Versus Placebo in the Treatment of Patients With Vascular Dementia or Mixed Dementia Completed NCT00261573 Phase 3 galantamine hydrobromide
21 A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Behavioral Disturbances in Patients With Dementia Completed NCT00253123 Phase 3 risperidone
22 A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia Completed NCT00249158 Phase 3 Risperidone
23 A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia Completed NCT00249145 Phase 3 risperidone
24 Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia Completed NCT00209456 Phase 3 DatSCAN
25 Donepezil Hydrochloride (E2020) in Dementia Associated With Cerebrovascular Disease Completed NCT00165737 Phase 3 Donepezil Hydrochloride
26 Rivastigmine Capsules in Patients With Probable Vascular Dementia Completed NCT00130338 Phase 3 Rivastigmine
27 Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia Completed NCT00099216 Phase 3 Rivastigmine
28 A Placebo-controlled Trial to Evaluate the Safety and Efficacy of Galantamine in the Treatment of Vascular Dementia Completed NCT00035191 Phase 3 galantamine
29 Serotonergic Pharmacotherapy for Agitation of Dementia Completed NCT00009204 Phase 3 Citalopram [Celexa];Perphenazine [Trilafon]
30 Optimized Remote Ischemic Conditioning (RIC) Treatment for Patients With Chronic Cerebral Ischemia Recruiting NCT03105141 Phase 2, Phase 3
31 The Clinical Trial of Chinese Herbal Medicine (SaiLuoTong) Capsule Recruiting NCT03789760 Phase 3 SaiLuoTong capsule;placebo
32 The Healthy Patterns Study Recruiting NCT03682185 Phase 3
33 MIND Diet Intervention and Cognitive Decline Active, not recruiting NCT02817074 Phase 3
34 Angioplasty and Stenting for Patients With Symptomatic Intracranial Atherosclerosis Not yet recruiting NCT02689037 Phase 3 Aspirin plus clopidogrel
35 Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia Not yet recruiting NCT03804229 Phase 3 Butylphthalide soft capsule;Placebo soft capsule
36 Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study Not yet recruiting NCT03785067 Phase 3 telmisartan 20mg + amlodipine 2.5mg +indapamide 1.25mg;Placebo oral capsule
37 Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia Terminated NCT00174382 Phase 3 Donepezil
38 The Clinical Trial of Chinese Herbal Medicine SaiLuoTong Capsule Unknown status NCT01978730 Phase 2 high dose group of SaiLuoTong capsule;low dose group of SaiLuoTong;the control group
39 Effect of Zydena (Udenafil) on Cerebral Blood Flow and Peripheral Blood Viscosity Unknown status NCT01466543 Phase 2 Zydena (Udenafil);Placebo
40 Asymptomatic Carotid Artery Plaque Study (ACAPS) Completed NCT00000469 Phase 2 aspirin;lovastatin
41 DAOIB for the Treatment of Cognitive Function and Behavioral and Psychological Symptoms of Dementia Completed NCT02103673 Phase 2 DAOIB;Placebo
42 Effect of Insulin Sensitizer Metformin on AD Biomarkers Completed NCT01965756 Phase 2 Metformin;Placebos
43 Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular Dementia Completed NCT01761227 Phase 2 Fufangdanshen Tablets;Placebo
44 Delta-THC in Dementia Completed NCT01608217 Phase 2 delta-9-tetrahydrocannabinol (delta-THC);Placebo;Acetaminophen;Acetaminophen
45 Study of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency) Completed NCT01475578 Phase 2 STA-1;Ergoloid Mesylates tablet
46 Efficacy and Safety of TMBCZG in Mild to Moderate Vascular Dementia Recruiting NCT03230071 Phase 2 TMBCZG
47 A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia Recruiting NCT02886494 Phase 2 BAC;Matched placebo
48 Perfusion by Arterial Spin Labelling Following Single Dose Tadalafil in Small Vessel Disease (PASTIS) Trial Active, not recruiting NCT02450253 Phase 2 Tadalafil;Placebo
49 n-3 PUFA for Vascular Cognitive Aging Active, not recruiting NCT01953705 Phase 2 Omega 3 PUFA;Placebo
50 Prevention for the Restenosis of Intracranial Artery Stent Implantation Treated With Herbal Medicine C117 Not yet recruiting NCT03008798 Phase 2 Herbal Medicine C-117;The Placebo of Herbal Medicine C-117

Search NIH Clinical Center for Cerebral Atherosclerosis

Cochrane evidence based reviews: intracranial arteriosclerosis

Genetic Tests for Cerebral Atherosclerosis

Anatomical Context for Cerebral Atherosclerosis

MalaCards organs/tissues related to Cerebral Atherosclerosis:

42
Brain, Heart, Smooth Muscle, Testes, Bone, Retina, Endothelial

Publications for Cerebral Atherosclerosis

Articles related to Cerebral Atherosclerosis:

(show top 50) (show all 141)
# Title Authors Year
1
Intracranial Arterial Calcificationes Can Reflect Cerebral Atherosclerosis Burden. ( 30375758 )
2019
2
Plasma miR-126 and miR-143 as Potential Novel Biomarkers for Cerebral Atherosclerosis. ( 30309729 )
2019
3
Width of sulcus and thickness of gyrus in patients with cerebral atherosclerosis: a new tool for the prevention of vascular cognitive impairment. ( 30673038 )
2018
4
The Impact of Cerebral Atherosclerosis According to Location on Prognosis after Coronary Artery Bypass Grafting. ( 30408800 )
2018
5
Ethnic Differences in Intracranial Artery Tortuosity: A Possible Reason for Different Locations of Cerebral Atherosclerosis. ( 29402073 )
2018
6
Location of cerebral atherosclerosis: Why is there a difference between East and West? ( 27145795 )
2018
7
Interarm Systolic and Diastolic Blood Pressure Difference Is Diversely Associated With Cerebral Atherosclerosis in Noncardioembolic Stroke Patients. ( 28985258 )
2017
8
Proteomic analysis and comparison of intra‑ and extracranial cerebral atherosclerosis responses to hyperlipidemia in rabbits. ( 28677755 )
2017
9
Differential impact of serum total bilirubin level on cerebral atherosclerosis and cerebral small vessel disease. ( 28319156 )
2017
10
Is obstructive sleep apnea associated with the presence of intracranial cerebral atherosclerosis? ( 28168435 )
2017
11
Erratum: The role of shear stress and arteriogenesis in maintaining vascular homeostasis and preventing cerebral atherosclerosis. ( 30276281 )
2016
12
Intake of antioxidants and B vitamins is inversely associated with ischemic stroke and cerebral atherosclerosis. ( 27698959 )
2016
13
Value of higher-resolution MRI in assessing middle cerebral atherosclerosis and predicting capsular warning syndrome. ( 27080075 )
2016
14
A pathological perspective on the natural history of cerebral atherosclerosis. ( 25854637 )
2015
15
Susceptibility vessel signs on T2*-weighted gradient echo images in patients with cerebral atherosclerosis. ( 25231582 )
2014
16
Letter by Tsuda regarding article, "Serum alkaline phosphatase and phosphate in cerebral atherosclerosis and functional outcomes after cerebral infarction". ( 24448990 )
2014
17
Response to letter regarding article, "Serum alkaline phosphatase and phosphate in cerebral atherosclerosis and functional outcomes after cerebral infarction". ( 24448989 )
2014
18
Relationship between cerebral atherosclerosis and leukoaraiosis in aged patients: results from DSA. ( 24033698 )
2014
19
Serum alkaline phosphatase and phosphate in cerebral atherosclerosis and functional outcomes after cerebral infarction. ( 24021686 )
2013
20
Elevated Aβ42 in aged, non-demented individuals with cerebral atherosclerosis. ( 23919773 )
2013
21
Cerebral atherosclerosis is associated with cystic infarcts and microinfarcts but not Alzheimer pathologic changes. ( 23887837 )
2013
22
Nonrelevant cerebral atherosclerosis is a strong prognostic factor in acute cerebral infarction. ( 23686972 )
2013
23
Different impact of hyperhomocysteinemia on cerebral small vessel ischemia and cervico-cerebral atherosclerosis in non-stroke individuals. ( 23218488 )
2013
24
The association between cerebral atherosclerosis and arterial stiffness in acute ischemic stroke. ( 21974846 )
2011
25
Gender differences in risk factors for intracranial cerebral atherosclerosis among asymptomatic subjects. ( 21497768 )
2011
26
Increases in cerebral atherosclerosis according to CHADS2 scores in patients with stroke with nonvalvular atrial fibrillation. ( 21350200 )
2011
27
Plasma total homocysteine and the methylenetetrahydrofolate reductase 677C>T polymorphism do not contribute to the distribution of cervico-cerebral atherosclerosis in ischaemic stroke patients. ( 20825473 )
2011
28
Cerebral atherosclerosis causes neurodegenerative diseases. ( 20037498 )
2010
29
Intracranial angioplasty and stenting for cerebral atherosclerosis: a position statement of the American Society of Interventional and Therapeutic Neuroradiology, Society of Interventional Radiology, and the American Society of Neuroradiology. ( 19560016 )
2009
30
Endothelial function in lacunar infarction: a comparison of lacunar infarction, cerebral atherosclerosis and control group. ( 19556769 )
2009
31
Large vessel cerebral atherosclerosis is not in direct association with neuropathological lesions of Alzheimer's disease. ( 19521084 )
2009
32
Classic risk factors for atherosclerosis are not major determinants for location of extracranial or intracranial cerebral atherosclerosis. ( 19169042 )
2009
33
Risk factors of intracranial cerebral atherosclerosis among asymptomatics. ( 17690548 )
2007
34
Intracranial angioplasty and stenting for cerebral atherosclerosis: new treatments for stroke are needed! ( 16622698 )
2006
35
Correlation of coronary and cerebral atherosclerosis: difference between extracranial and intracranial arteries. ( 16340186 )
2006
36
Intracranial angioplasty & stenting for cerebral atherosclerosis: a position statement of the American Society of Interventional and Therapeutic Neuroradiology, Society of Interventional Radiology, and the American Society of Neuroradiology. ( 16223717 )
2005
37
Intracranial angioplasty & stenting for cerebral atherosclerosis: a position statement of the American Society of Interventional and Therapeutic Neuroradiology, Society of Interventional Radiology, and the American Society of Neuroradiology. ( 16221663 )
2005
38
[The predictors of ischemic stroke in cerebral atherosclerosis and ischemic heart disease]. ( 15997569 )
2005
39
Intracranial angioplasty and stent placement for cerebral atherosclerosis. ( 15101521 )
2004
40
Cerebral atherosclerosis and oxidative stress in Alzheimer's disease. ( 14757939 )
2003
41
Cerebral atherosclerosis and mild Alzheimer's disease. ( 12855821 )
2003
42
Cerebral atherosclerosis and coronary calcification. ( 12364716 )
2002
43
Cerebral atherosclerosis causes neurogenic hypertension. ( 11988586 )
2002
44
Cerebral atherosclerosis as predictor of stroke and mortality in representative elderly population. ( 11779914 )
2002
45
Cerebral atherosclerosis occurs spontaneously in homozygous WHHL rabbits. ( 11368997 )
2001
46
Early lesions of cerebral atherosclerosis from induced hypertension in Watanabe heritable hyperlipidemic rabbits. ( 11193506 )
2000
47
The influence of the degree of cerebral atherosclerosis on the changes in hemostatic system in patients with ischemic brain disease and atherosclerotic encephalopathy. ( 10645149 )
1999
48
Cerebral atherosclerosis in Parkinsonian patients. ( 18591095 )
1998
49
Relation of plasma homocyst(e)ine to cerebral infarction and cerebral atherosclerosis. ( 9836754 )
1998
50
The lipoprotein profile of young adults with cerebral atherosclerosis. ( 9031424 )
1996

Variations for Cerebral Atherosclerosis

Expression for Cerebral Atherosclerosis

Search GEO for disease gene expression data for Cerebral Atherosclerosis.

Pathways for Cerebral Atherosclerosis

GO Terms for Cerebral Atherosclerosis

Cellular components related to Cerebral Atherosclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular vesicle GO:1903561 9.46 APOA1 APOE
2 collagen-containing extracellular matrix GO:0062023 9.43 APOA1 APOE
3 high-density lipoprotein particle GO:0034364 9.4 APOA1 APOE
4 very-low-density lipoprotein particle GO:0034361 9.37 APOA1 APOE
5 endocytic vesicle lumen GO:0071682 9.32 APOA1 APOE
6 low-density lipoprotein particle GO:0034362 9.26 APOA1 APOE
7 chylomicron GO:0042627 9.16 APOA1 APOE
8 intermediate-density lipoprotein particle GO:0034363 8.96 APOA1 APOE
9 discoidal high-density lipoprotein particle GO:0034365 8.62 APOA1 APOE

Biological processes related to Cerebral Atherosclerosis according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of inflammatory response GO:0050728 9.61 APOA1 APOE
2 cholesterol homeostasis GO:0042632 9.6 APOA1 APOE
3 cholesterol metabolic process GO:0008203 9.59 APOA1 APOE
4 retinoid metabolic process GO:0001523 9.58 APOA1 APOE
5 cholesterol biosynthetic process GO:0006695 9.58 APOA1 APOE
6 triglyceride homeostasis GO:0070328 9.57 APOA1 APOE
7 triglyceride catabolic process GO:0019433 9.56 APOA1 APOE
8 cholesterol efflux GO:0033344 9.55 APOA1 APOE
9 lipoprotein metabolic process GO:0042157 9.54 APOA1 APOE
10 reverse cholesterol transport GO:0043691 9.52 APOA1 APOE
11 high-density lipoprotein particle remodeling GO:0034375 9.51 APOA1 APOE
12 positive regulation of lipid biosynthetic process GO:0046889 9.49 APOA1 APOE
13 high-density lipoprotein particle assembly GO:0034380 9.48 APOA1 APOE
14 phospholipid efflux GO:0033700 9.46 APOA1 APOE
15 chylomicron assembly GO:0034378 9.43 APOA1 APOE
16 high-density lipoprotein particle clearance GO:0034384 9.4 APOA1 APOE
17 positive regulation of cholesterol esterification GO:0010873 9.37 APOA1 APOE
18 very-low-density lipoprotein particle remodeling GO:0034372 9.32 APOA1 APOE
19 chylomicron remodeling GO:0034371 9.26 APOA1 APOE
20 regulation of Cdc42 protein signal transduction GO:0032489 9.16 APOA1 APOE
21 regulation of cholesterol transport GO:0032374 8.96 APOA1 APOE
22 lipoprotein biosynthetic process GO:0042158 8.62 APOA1 APOE

Molecular functions related to Cerebral Atherosclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phospholipid binding GO:0005543 9.4 APOA1 APOE
2 amyloid-beta binding GO:0001540 9.37 APOA1 APOE
3 cholesterol binding GO:0015485 9.32 APOA1 APOE
4 lipid transporter activity GO:0005319 9.26 APOA1 APOE
5 cholesterol transporter activity GO:0017127 9.16 APOA1 APOE
6 lipoprotein particle binding GO:0071813 8.96 APOA1 APOE
7 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 8.62 APOA1 APOE

Sources for Cerebral Atherosclerosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....